Type 2 Diabetes Trial, Not Yet Recruiting NCT07520305 Sponsor: Beijing Chao Yang Hospital Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Not Yet Recruiting

NCT07520305
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 to 65 years, of any gender
  • People who have recently been diagnosed with type 2 diabetes and have not yet taken any diabetes medication
  • People whose HbA1c blood sugar level at the screening visit is between 7.0% and 9.0% (a blood test result that reflects average blood sugar over roughly 3 months)
  • People who understand what the study involves, including its potential benefits and risks, and who have voluntarily signed a consent form

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a type of diabetes other than type 2, such as type 1 diabetes, latent autoimmune diabetes in adults, or diabetes caused by another medical condition (such as certain hormonal disorders)
  • People who have had a serious acute diabetes complication, such as diabetic ketoacidosis or a diabetic hyperosmolar coma, in the past 6 months
  • People who have had a low blood sugar episode (hypoglycaemia) in the past 6 months
  • People who have a history of moderate to severe heart failure, or who have had a serious heart or cardiovascular event (such as a heart attack, stroke, mini-stroke, unstable chest pain, or heart surgery including stents or valve procedures) in the 6 months before the screening visit
  • People who have a history of chronic active hepatitis, or serious problems with their liver, kidneys, or thyroid
  • People who have a history of cancer
  • People who have a history of digestive or bowel conditions that affect how food is absorbed (such as severe diarrhoea, constipation, irritable bowel syndrome, inflammatory bowel disease, active stomach ulcers, or acute gallbladder inflammation), or who have had bowel surgery or gallbladder removal within the past year
  • People who have had surgery or a serious injury in the past 6 months, or who are planning to have surgery during the study
  • People who are currently experiencing a serious infection, severe anaemia, or a dangerously low white blood cell count
  • People who are pregnant, breastfeeding, or planning to become pregnant or father a child during the study or within 3 months after it ends
  • People who have taken immunosuppressants, steroids, anti-diarrhoeal drugs, antibiotics, cholesterol-lowering medications, or other gut motility medications in the past 3 months
  • People who have used other medications that can affect blood sugar levels in the past 3 months
  • People who have used probiotic or prebiotic products in the 3 months before the screening visit
  • People who have lactose intolerance, a known or suspected allergy to the probiotics used in the study, a history of drug allergies, or allergic conditions
  • People whose weight has changed by 5 kg or more in the past 3 months, or who are planning to take weight-control medication during the study
  • People who have a history of mental illness or epilepsy, or who are currently taking antidepressant medications
  • People who have a history of heavy alcohol use (more than 40 grams of alcohol per day for men, or more than 20 grams per day for women)
  • People who have taken part in another clinical trial in the past 3 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Guang Wang, Beijing Chao Yang Hospital

Phone: 010-85231710

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Beijing Chao Yang Hospital
Registry
ClinicalTrials.gov
Start date
20 April 2026
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

HbA1c change

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov